OBI vs. FUM, MPH, SCLP, ORPH, REDX, ETX, TRX, SBTX, COS, and C4XD
Should you be buying Ondine Biomedical stock or one of its competitors? The main competitors of Ondine Biomedical include Futura Medical (FUM), Mereo BioPharma Group plc (MPH.L) (MPH), Scancell (SCLP), Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), Tissue Regenix Group (TRX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), and C4X Discovery (C4XD). These companies are all part of the "biotechnology" industry.
Ondine Biomedical vs.
Ondine Biomedical (LON:OBI) and Futura Medical (LON:FUM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and community ranking.
Futura Medical received 185 more outperform votes than Ondine Biomedical when rated by MarketBeat users. However, 100.00% of users gave Ondine Biomedical an outperform vote while only 64.36% of users gave Futura Medical an outperform vote.
20.6% of Ondine Biomedical shares are held by institutional investors. Comparatively, 35.7% of Futura Medical shares are held by institutional investors. 36.7% of Ondine Biomedical shares are held by insiders. Comparatively, 32.1% of Futura Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Futura Medical had 1 more articles in the media than Ondine Biomedical. MarketBeat recorded 1 mentions for Futura Medical and 0 mentions for Ondine Biomedical. Futura Medical's average media sentiment score of 0.59 beat Ondine Biomedical's score of 0.00 indicating that Futura Medical is being referred to more favorably in the news media.
Ondine Biomedical has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, Futura Medical has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.
Futura Medical has higher revenue and earnings than Ondine Biomedical. Futura Medical is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.
Ondine Biomedical has a net margin of 0.00% compared to Futura Medical's net margin of -44.68%. Futura Medical's return on equity of -47.43% beat Ondine Biomedical's return on equity.
Summary
Futura Medical beats Ondine Biomedical on 10 of the 15 factors compared between the two stocks.
Get Ondine Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ondine Biomedical Competitors List
Related Companies and Tools
This page (LON:OBI) was last updated on 1/21/2025 by MarketBeat.com Staff
